Nang Kuang Pharmaceutical Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Taipei Taiwan (1963)
Status: No NME R&D (1963)

Organization Overview

First Clinical Trial
2009
NCT02074267
First Marketed Drug
2016
linezolid (zyvox)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Nang Kuang Pharmaceutical Co., Ltd. | NANG KUANG PHARM CO

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cardiovascular Diseases (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Esophageal Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hypercholesterolemia (Phase 4)

Pain, Postoperative (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 12